Following the immediate cancellation of the letter license agreement, Pfizer's returns its FDA approved Oxecta
(oxycodone HCl) product to Acura Pharmaceuticals.
, a version of Oxycodone with an abuse-deterring formulation that
M2 PHARMA-July 2, 2013-Acura announces commercial expansion of OXECTA
by Pfizer in US(C)2013 M2 COMMUNICATIONS
M2 EQUITYBITES-July 2, 2013-Acura announces commercial expansion of OXECTA
by Pfizer in US(C)2013 M2 COMMUNICATIONS http://www.m2.com
In addition, the company has licensed certain claims in this patent to Pfizer Inc (NYSE: PFE) which utilises the former's AVERSION technology in its Oxecta
(oxycodone HCl) tablets CII.
Speciality pharmaceutical company Acura Pharmaceuticals Inc (NASDAQ:ACUR) reported on Thursday that it has received notification from a generic sponsor of the filing of an Abbreviated New Drug Application (ANDA) for a generic drug listing OXECTA
(oxycodone HCl) Tablets CII as the reference listed drug.
However, Acura's fourth product with its AVERSION Technology, OXECTA
(oxycodone hydrochloride) Tablets CII, is being commercialised by Pfizer, who will retain all rights and obligations to OXECTA
M2 PHARMA-January 24, 2012-Acura announces commercial availability of OXECTA
(oxycodone HCl, USP) Tablets CII(C)2012 M2 COMMUNICATIONS
Acura Pharmaceuticals Inc (Nasdaq:ACUR), a speciality pharmaceutical company, announced on Monday that it has been informed by Pfizer Inc (NYSE: PFE) that OXECTA
(oxycodone HCl, USP) Tablets CII are now commercially available.